PT-262

PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity[1][2].

Product Specifications

CAS Number

[86811-36-1]

UNSPSC

12352005

Target

Apoptosis; CDK; ERK; ROCK

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; MAPK/ERK Pathway; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/pt-262.html

Concentration

10mM

Purity

99.21

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C(N1CCCCC1)=C2Cl)C3=C(N=CC=C3)C2=O

Molecular Formula

C14H13ClN2O2

Molecular Weight

276.72

References & Citations

[1]Tzu-Sheng Hsu, et al. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel synthetic compound induces lung carcinoma cell death associated with inhibiting ERK and CDC2 phosphorylation via a p53-independent pathway. Cancer Chemother Pharmacol. 2008 Oct;62 (5) :799-808.|[2]Chih-Chien Tsai, et al. 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. Biochem Pharmacol. 2011 Apr 1;81 (7) :856-65.